Repatha vs Praluent: Long-Term Durability of LDL Lowering for Women

What Is the Core Difference Between Repatha and Praluent?

Repatha (evolocumab) and Praluent (alirocumab) are both fully human monoclonal antibodies that block PCSK9, a liver enzyme that degrades LDL receptors. Blocking PCSK9 keeps more receptors on the liver surface, so more LDL is cleared from the bloodstream. The two drugs work by the same mechanism, target the same protein, and produce LDL reductions that are clinically similar. The practical differences come down to dosing schedules, the size of the cardiovascular outcomes data, and a small but real difference in how each drug performed in distinct high-risk populations.

How Each Drug Reaches the Same Target

Evolocumab binds a slightly different epitope on PCSK9 than alirocumab, but both block PCSK9 binding to the LDL receptor with high affinity. Pharmacokinetic data show that after subcutaneous injection, both agents reach peak serum concentration in 3 to 7 days and have half-lives of roughly 11 to 17 days, which explains the two-week dosing intervals.

The One Practical Dosing Distinction

Repatha offers a monthly 420 mg auto-injector (three 140 mg pens administered within 30 minutes) that some women prefer over every-other-week injections. Praluent now has an FDA-approved 300 mg once-monthly dose, approved in 2023, which closes that convenience gap. If adherence to a two-week schedule is the reason you are considering a switch, the monthly option now exists for both drugs.

How Durable Is LDL Lowering Over Years? What the Trials Show

Neither drug loses potency over time. This is the single most reassuring finding across both the major cardiovascular outcomes trials and the open-label extension studies. LDL reductions achieved at week 12 are maintained at years two, three, and four without dose escalation.

FOURIER: Repatha's Four-Year Landmark

The FOURIER trial randomized 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) to evolocumab or placebo on top of statin therapy. Median follow-up was 2.2 years. Evolocumab reduced LDL by a median of 59 percent, from a baseline of 92 mg/dL to 30 mg/dL. The primary composite endpoint (cardiovascular death, MI, stroke, coronary revascularization, or unstable angina) was reduced by 15 percent (HR 0.85, 95% CI 0.79-0.92). Secondary endpoints, which excluded revascularization and unstable angina, showed a 20 percent relative risk reduction (HR 0.80, 95% CI 0.73-0.88). LDL remained suppressed at every time point measured through the trial, with no evidence of antibody formation reducing drug effect.

The FOURIER open-label extension, FOURIER-OLE, followed patients for up to 8.4 years total. Those who received evolocumab from the start maintained their LDL reduction and showed a lower rate of cardiovascular events than those who crossed over later, suggesting that earlier and longer PCSK9 inhibition compounds benefit over time.

ODYSSEY OUTCOMES: Praluent's Post-ACS Evidence

The ODYSSEY OUTCOMES trial randomized 18,924 patients who had experienced an acute coronary syndrome within the prior 1 to 12 months to alirocumab or placebo, again on top of maximally tolerated statin therapy. Median follow-up was 2.8 years. Alirocumab reduced LDL by approximately 54 percent. The primary endpoint (coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization) was reduced by 15 percent (HR 0.85, 95% CI 0.78-0.93). Among patients with baseline LDL at or above 100 mg/dL, the absolute risk reduction was larger, and alirocumab was associated with a statistically significant reduction in all-cause mortality (HR 0.85, 95% CI 0.73-0.98) in that pre-specified subgroup.

Both trials demonstrate that LDL lowering is durable across the observation period. Neither study found the antibody response waning or the drug losing clinical effectiveness over time.

How Women Specifically Fared in These Trials

Women represented roughly 25 percent of participants in both FOURIER and ODYSSEY OUTCOMES. That is a known limitation, and the sex-disaggregated data show a pattern worth discussing honestly.

In FOURIER, the relative risk reduction in the primary endpoint was directionally consistent for women and men, but the confidence interval for women crossed 1.0 in some subgroup analyses, meaning the female-only result was not statistically significant on its own. The trial was not powered to detect sex differences. A 2020 meta-analysis of PCSK9 inhibitor trials covering 68,123 patients found that the relative cardiovascular benefit of PCSK9 inhibitors is similar between sexes (RR 0.84 in women vs 0.85 in men) but that women's absolute risk reduction is smaller in trials that enrolled lower-risk women. This matters because the benefit you personally get depends heavily on your baseline ASCVD risk, not just your LDL number.

In ODYSSEY OUTCOMES, the post-ACS population had a higher baseline risk for both sexes, and the benefit in women was more consistent, though the trial remained underpowered for sex-stratified analysis. Alirocumab's FDA label does not identify sex as a modifier of effect, and Repatha's FDA label is similarly silent on sex-differential dosing.

Why Hormonal Status Changes Your Cardiovascular Risk

Before menopause, estrogen supports vascular endothelial function and tends to keep LDL lower and HDL higher than in age-matched men. At the menopause transition, LDL rises by approximately 10 to 14 mg/dL on average, a shift documented in longitudinal data from the Study of Women's Health Across the Nation (SWAN). This means the decision to start a PCSK9 inhibitor may become more urgent in early postmenopause, even if your LDL was well-controlled at 45.

For women with familial hypercholesterolemia (FH), the estrogen-mediated LDL benefit is largely absent because the LDL receptor is dysfunctional. These women carry high ASCVD risk during reproductive years and often require PCSK9 inhibitors well before menopause.

PCOS and Dyslipidemia

Women with polycystic ovary syndrome (PCOS) have a distinct lipid phenotype: elevated triglycerides, low HDL, and small dense LDL particles, even when total LDL appears normal. AHA/ACC guidelines recognize PCOS as a risk-enhancing condition for ASCVD. PCSK9 inhibitor trials did not specifically enroll PCOS populations, so data are extrapolated from general trial results. If you have PCOS and are considering a PCSK9 inhibitor, a lipid specialist or cardiologist with experience in women's metabolic health should guide that conversation.

Pregnancy, Lactation, and Contraception: What You Must Know Before Starting Either Drug

Neither evolocumab nor alirocumab is safe to use during pregnancy. Both drugs must be stopped before conception attempts.

Pregnancy Data

LDL cholesterol rises physiologically during pregnancy to support fetal sterol synthesis. There is no established medical indication to treat elevated LDL during pregnancy with a PCSK9 inhibitor, and animal data for evolocumab showed adverse fetal effects at high doses in some models. FDA prescribing information for evolocumab states that the drug should be discontinued when pregnancy is recognized and advises against use during pregnancy. Alirocumab carries the same guidance. Neither drug has a formal pregnancy category under the old A/B/C/D/X system (the FDA moved to narrative labeling in 2015), but the narrative language is clear: avoid use.

There are case reports of inadvertent first-trimester exposure with no obvious pattern of fetal harm, but the numbers are far too small to draw reassuring conclusions. Do not rely on those case reports as a green light.

Lactation

It is unknown whether evolocumab or alirocumab transfers into human breast milk. IgG1 antibodies, which is the class both drugs belong to, are known to transfer into breast milk in small amounts. Given that lipid lowering is not urgent in the postpartum period for most women, the standard recommendation is to avoid both drugs during breastfeeding. Discuss this timing explicitly with your cardiologist and your OB if you plan to nurse.

Contraception Requirement

Women of reproductive age starting either PCSK9 inhibitor should use reliable contraception throughout treatment. If you stop the drug to try to conceive, allow at least one full half-life (roughly 17 to 25 days depending on the agent and your clearance) before conception, though most clinicians advise stopping one to two full dosing cycles before attempting pregnancy to be conservative.

Who Is Each Drug Right For? A Life-Stage View

Premenopausal Women With Familial Hypercholesterolemia

Both drugs are appropriate. FH is the clearest indication for PCSK9 inhibition in younger women. Because neither drug is safe in pregnancy, a solid contraceptive plan is mandatory before starting. Women with heterozygous FH who want to conceive in the near future should have a very specific conversation about timing.

Postmenopausal Women With Established ASCVD

This is the group with the strongest evidence base from the trials. Both drugs are appropriate. If you already had a heart attack or stroke, the absolute risk reduction from either agent is clinically meaningful. The choice between evolocumab and alirocumab in this group typically comes down to formulary access, cost, and the monthly vs every-other-week injection preference.

Women After an Acute Coronary Syndrome

ODYSSEY OUTCOMES enrolled specifically a post-ACS population and showed a mortality signal in the highest-risk subgroup. That makes alirocumab a defensible first choice in the immediate post-ACS window, though most guidelines, including the 2022 ACC/AHA Chest Pain Guideline, do not rank the two agents differently.

Women Who Are Statin-Intolerant

Both drugs work without statins, though they are most effective in combination. For women who cannot tolerate any statin dose, PCSK9 inhibitors remain fully active. Statin intolerance is reported somewhat more often in women than men, though the reasons are debated. If myalgia has stopped you from taking statins, your prescriber should confirm true statin intolerance with a re-challenge before moving you to a PCSK9 inhibitor alone.

Who Is Not a Good Candidate

Women who are pregnant, planning pregnancy imminently without reliable contraception, or breastfeeding should not start either drug. Women with LDL that is mildly elevated and no ASCVD risk factors generally do not meet the threshold for PCSK9 inhibitor use; first-line therapy is statin plus lifestyle modification.

Switching From Repatha to Praluent (or Vice Versa): What Actually Happens

Switching between evolocumab and alirocumab is clinically feasible. LDL lowering is preserved. There is no rebound, no washout period required, and no immunologic penalty for switching.

Reasons to Switch

The most common reason women switch is insurance formulary change. One drug may be preferred (meaning lower cost-sharing) on your plan in a given year. A second reason is injection-site reactions; some women develop localized redness or swelling with one formulation that resolves when they switch. A third reason is the monthly vs every-other-week preference when life circumstances change.

What to Expect When You Switch

Your LDL will remain suppressed through the transition. If you switch from the Repatha 420 mg monthly auto-injector to Praluent 300 mg monthly, the mechanism and the approximate dose are comparable. You can generally give your first dose of the new drug at the time the next dose of the old drug would have been due, though your prescriber may choose to overlap for one cycle to avoid any gap in coverage.

Does the Cardiovascular Benefit Transfer?

This is the key question, and the honest answer is: we do not have a long-term outcomes trial of patients who switched midway through therapy. What we know is that LDL lowering is the primary mediator of benefit and that both drugs achieve similar LDL targets. The Mendelian randomization data supporting lower LDL as a causal driver of reduced ASCVD risk apply equally to both drugs. There is no biological reason to expect the cardiovascular protection to evaporate when you switch agents.

Durability Beyond Two Years: What the Extension Data Tell Us

The open-label extension from FOURIER provides the longest prospective follow-up for a PCSK9 inhibitor. In FOURIER-OLE, patients who remained on evolocumab for up to 8.4 years maintained a mean LDL around 30 mg/dL with no evidence of anti-drug antibody formation affecting clinical outcomes. Cardiovascular event rates continued to diverge between early and late initiators, with those on the drug longest having the lowest event rates.

For alirocumab, the longest continuous data come from the ODYSSEY LONG TERM trial, a 78-week study in high-risk patients, and from pooled analyses of alirocumab open-label extensions reaching two to three years. LDL lowering remained consistent throughout.

Neither drug produces tachyphylaxis. The receptor-blocking mechanism does not desensitize, the liver does not upregulate PCSK9 production enough to overcome the antibody's effect at therapeutic doses, and the antibody itself does not generate a neutralizing immune response in the vast majority of patients.

Comparing Side-Effect Profiles in Women

Both drugs are generally well tolerated. The most common adverse effects are injection-site reactions (redness, itching, bruising at the injection site), which occur in 2 to 4 percent of users in trials. Nasopharyngitis and influenza-like symptoms appear at similar rates between drug and placebo across both trials, suggesting these are incidental rather than drug-caused.

Neurocognitive events received attention early in PCSK9 inhibitor development. The EBBINGHAUS trial, a prospective cognitive substudy of FOURIER with 1,204 participants, found no significant difference in cognitive performance between evolocumab and placebo over 19 months, even at LDL levels below 20 mg/dL. Women-specific neurocognitive data from EBBINGHAUS were not published separately, but no sex-differential signal was identified.

For women in perimenopause who report brain fog, it is worth separating estrogen-deficiency cognitive symptoms from any theoretical PCSK9 inhibitor effect. The EBBINGHAUS data are reassuring that the drug itself is not the cause.

Cost, Access, and Real-World Adherence

Both drugs carry list prices above $5,000 per year in the United States before manufacturer rebates. In practice, most commercially insured patients pay $0 to $25 per month through manufacturer copay assistance programs. Medicare patients have more variable access. Real-world adherence studies show that approximately 50 to 60 percent of patients who are prescribed a PCSK9 inhibitor remain on it at one year, with cost and prior authorization burden being the primary drivers of discontinuation.

Prior authorization is required by most payers. Typical criteria include: documented ASCVD or FH, LDL above 70 mg/dL (or above 100 mg/dL for some payers) despite maximally tolerated statin plus ezetimibe, and documented statin intolerance if a statin is not prescribed. Understanding these criteria before your appointment saves weeks of delay.

The Evidence Gap for Women: What We Are Extrapolating

Women were underrepresented in both landmark trials, making up only about 25 percent of each enrolled population despite representing at least 45 to 50 percent of people with ASCVD. A 2019 JACC paper on sex differences in ASCVD trial enrollment documented this persistent gap across cardiovascular trials. The absolute event rates in women enrolled in FOURIER and ODYSSEY OUTCOMES were lower than in men, partly because women with ASCVD tend to be older at enrollment and have different comorbidity profiles.

What this means for you: the relative risk reduction data are likely generalizable, but your personal absolute benefit depends on your individual 10-year ASCVD risk score, your baseline LDL, and your cardiovascular history. Calculators like the pooled cohort equations are a starting point, though they are known to overestimate risk in some women of color and underestimate risk in women with autoimmune conditions or a history of preeclampsia.

A Practical Decision Framework: Repatha or Praluent?

The choice for most women comes down to four factors.

First, formulary. Check your insurance plan's preferred drug list before the prescribing conversation. If your plan prefers one agent, start there; the clinical outcomes are equivalent.

Second, dosing schedule preference. If a monthly injection fits your life better than every-other-week, both the Repatha 420 mg auto-injector and the Praluent 300 mg prefilled pen are monthly options.

Third, your specific cardiovascular history. If you are choosing in the immediate aftermath of an acute coronary syndrome, the ODYSSEY OUTCOMES all-cause mortality signal in high-LDL patients is a reasonable (if not definitive) argument for alirocumab. Your cardiologist may weigh this differently.

Fourth, reproductive planning. If you are in your reproductive years and there is any chance of pregnancy in the near term, the mandatory contraception requirement and the need to stop the drug before conception should be part of the prescribing conversation before you fill the first prescription.